Investment
Features
FeesSafety
Academy
More
Pluang+

Compare United States Copper Index Fund (CPER) vs Novavax Inc (NVAX) Price & Performance

United States Copper Index FundTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

United States Copper Index Fund vs Novavax Inc — how do they compare? United States Copper Index Fund trades at $38.29, while Novavax Inc trades at $8.46 (market cap $1.38B). The key difference: United States Copper Index Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

CPERNVAX
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$40.60$11.19
52-Week Low
$27.21$6.22
Market Cap
$1.38B
Enterprise Value
$889.29M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

United States Copper Index Fund

CPER, the United States Copper Index Fund, trades at $37.94, down 0.13% on the day, with a bullish technical signal driven by moving averages. Recent news highlights copper's strong performance tied to AI and electrification demand, with articles from 24/7 Wall Street and Reuters in July 2026 noting copper's 33% annual gain and structural demand drivers. Key support and resistance cluster around $38.

The outlook for CPER remains positive given copper's fundamental role in energy transition and AI infrastructure, though risks include potential global manufacturing weakness and substitution threats from aluminum. Investor sentiment is buoyant, but price sensitivity to macroeconomic trends warrants caution.

Novavax Inc

Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.

The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About United States Copper Index Fund

CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.

Read more on CPER

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX